Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. and covers a range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. SafeCoat Medical Inc.'s technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides.


CSE:ASEP - Post by User

Post by XeniaTechieon Dec 03, 2021 1:17pm
114 Views
Post# 34195668

ground floor opportunity to invest in life saving tech

ground floor opportunity to invest in life saving tech

With the dramatic statistics around sepsis, killing 11M people per year, 1:5 with sepsis dying, there's a massive opportunity for ASEP where there are currently 0 approved treatments. $ASEP is developing a treatment for biofilms which accounts for 65% of bacterial infections leading to sepsis. 


No doubt there’s a significant human need in the unaddressed sepsis treatment, but further amplifying their market opportunity, sepsis affects animals as well. I’ve just come across the fact that ASEP is partnered with a global top 10 largest vet-pharmaceutical company, Vetoquinol.

 
<< Previous
Bullboard Posts
Next >>